SecSonar.com

Genelux Corporation (GNLX)

Genelux Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Genelux Corporation (GNLX) is a Biotechnology company based in US with a market capitalization of $114.7M. Revenue grew 0.0% year-over-year and free cash flow was negative at -$26.4M. This page tracks GNLX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 24 employees · IPO Jan 26, 2023

Valuation

Valuation & price

$2.92 · as of May 17, 2026 · -64.6% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

9.94

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.24$5.29$2.35Jul 25Dec 25Jun 26Jul 7, 25$2.90Jul 9, 25$3.46Jul 11, 25$3.43Jul 15, 25$3.08Jul 17, 25$3.40Jul 21, 25$3.51Jul 23, 25$3.60Jul 25, 25$3.34Jul 29, 25$3.55Jul 31, 25$3.39Aug 4, 25$3.51Aug 6, 25$3.59Aug 8, 25$3.15Aug 12, 25$3.19Aug 14, 25$3.41Aug 19, 25$3.43Aug 21, 25$3.44Aug 25, 25$3.74Aug 27, 25$3.64Aug 29, 25$3.33Sep 3, 25$3.31Sep 5, 25$3.37Sep 9, 25$3.67Sep 11, 25$3.65Sep 15, 25$3.92Sep 17, 25$3.91Sep 19, 25$4.16Sep 23, 25$4.34Sep 25, 25$4.21Sep 29, 25$4.25Oct 2, 25$4.39Oct 6, 25$4.54Oct 8, 25$4.75Oct 10, 25$5.07Oct 14, 25$5.28Oct 16, 25$5.36Oct 20, 25$6.51Oct 22, 25$6.31Oct 24, 25$7.82Oct 28, 25$7.64Oct 30, 25$7.96Nov 3, 25$8.24Nov 5, 25$7.84Nov 7, 25$5.42Nov 11, 25$5.98Nov 14, 25$5.32Nov 18, 25$5.06Nov 20, 25$4.64Nov 24, 25$5.10Nov 26, 25$5.59Dec 1, 25$4.90Dec 3, 25$4.65Dec 5, 25$4.64Dec 9, 25$4.55Dec 11, 25$4.40Dec 15, 25$4.08Dec 17, 25$4.15Dec 19, 25$4.20Dec 23, 25$4.34Dec 26, 25$4.37Dec 31, 25$4.36Jan 5, 26$3.48Jan 7, 26$3.39Jan 9, 26$2.80Jan 13, 26$2.74Jan 15, 26$2.56Jan 20, 26$2.73Jan 22, 26$2.88Jan 26, 26$2.85Jan 28, 26$2.76Jan 30, 26$2.66Feb 3, 26$2.72Feb 5, 26$2.35Feb 9, 26$2.46Feb 11, 26$2.42Feb 17, 26$2.56Feb 19, 26$2.68Feb 23, 26$2.70Feb 25, 26$2.97Feb 27, 26$2.98Mar 3, 26$2.58Mar 5, 26$2.69Mar 9, 26$2.83Mar 11, 26$2.78Mar 13, 26$2.60Mar 17, 26$2.62Mar 19, 26$2.54Mar 23, 26$2.48Mar 25, 26$2.65Mar 27, 26$2.48Apr 1, 26$2.56Apr 6, 26$2.73Apr 8, 26$2.64Apr 10, 26$2.54Apr 14, 26$2.64Apr 16, 26$2.77Apr 20, 26$2.65Apr 22, 26$2.54Apr 24, 26$2.52Apr 28, 26$2.53Apr 30, 26$2.67May 4, 26$2.85May 6, 26$2.87May 8, 26$3.11May 12, 26$2.97May 15, 26$2.92May 19, 26$2.80May 21, 26$2.92May 26, 26$3.01May 28, 26$3.07Jun 1, 26$2.97Jun 3, 26$3.00Jun 5, 26$2.93Jun 9, 26$2.98Jun 11, 26$2.88Jun 15, 26$3.02Jun 17, 26$2.85Jun 22, 26$2.92Jun 24, 26$2.85Jun 30, 26$2.90
$2.3052-week range$8.24
Loading valuation history…

Fundamentals

Key fundamentals

$114.7M

Market cap

0.0%

Revenue growth (YoY)

-7075.0%

Gross margin

-$26.4M

Free cash flow (USD)

-$12.9M

Net debt

Net cash position

18.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$11.1MFY 2023$170.0KFY 2024$8.0KFY 2025$8.0K
$0$8K

Free cash flow by year

2019 → 2025

FY 2019$-9.0MFY 2020$-7.2MFY 2021$-6.6MFY 2022$-3.6MFY 2023$-21.3MFY 2024$-21.6MFY 2025$-26.4M
-$9M-$26.4M

Gross margin by year

2022 → 2025

FY 202291.3%FY 2023-498.8%FY 2024-11187.5%FY 2025-7075.0%
91.3%-7075.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • Insider sellInsider Sell $563Smalling Ralph · Head of Regulatory · $562.6Jun 4, 2026Filing
  • Insider sellInsider Sell $30K · 10b5-1 PlanThomas John · Director · $29.8KJun 2, 2026Filing
  • Insider sellInsider Sell $804Smalling Ralph · Head of Regulatory · $804.5May 12, 2026Filing
  • Insider sellInsider Sell $8KZindrick Thomas · President and CEO · $8.2KMay 12, 2026Filing
  • Insider sellInsider Sell $2KCappello Joseph · Chief Technical Officer · $1.8KMay 12, 2026Filing
  • Insider sellInsider Sell $2KYu Yong · Chief Scientific Officer · $1.8KMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing

Questions

Frequently asked questions

What is Genelux Corporation's market cap?

Genelux Corporation (GNLX) has a market capitalization of $114.7M.

What is GNLX's P/E ratio?

A meaningful P/E ratio is not available for GNLX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is GNLX's price-to-book (P/B) ratio?

GNLX trades at 9.94 times book value per share.

Are insiders buying GNLX stock?

SEC Form 4 filings show no open-market insider buys at Genelux Corporation in the last 90 days (6 sells).

Same arena

Related companies in Biotechnology

PYXS

Pyxis Oncology, Inc.

$113.7M

ALPS

Alps Group Inc

$121.8M

MIST

Milestone Pharmaceuticals Inc.

$124.1M

CRDF

Cardiff Oncology, Inc.

$124.8M

IKT

Inhibikase Therapeutics, Inc.

$125.3M

SEER

Seer, Inc.

$103.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.